Suchergebnisse - "Marín-Niebla, Ana"

PubPharm (45)

1

PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma

enthalten in: EJHaem | 2023

von Ligero, M. | Simó, M. | Carpio, C. | +12

2

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

enthalten in: Blood advances | 2022

von Abrisqueta, P. | Medina, D. | Villacampa, G. | +12

3

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

enthalten in: Blood | 2022

von Rusconi, C. | Cheah, C. | Eyre, T. | +29

CommentIn: Blood. 2022 Oct 27;140(17):1835-1836. - PMID 36301632

4

IBRORS-MCL study : a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

enthalten in: International journal of hematology | 2022

von Sancho, J. | Marín-Niebla, A. | Fernández, S. | +22

5

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma

enthalten in: Leukemia & lymphoma | 2022

von Cabirta, A. | Hidalgo-Gómez, G. | Marín-Niebla, A. | +13

6

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

enthalten in: Blood advances | 2022

von Iacoboni, G. | Rejeski, K. | Villacampa, G. | +19

7

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia

enthalten in: Leukemia & lymphoma | 2022

von Panayiotidis, P. | Tumyan, G. | Thieblemont, C. | +11

8

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

enthalten in: International journal of hematology | 2022

von Sancho, J. | Marín-Niebla, A. | Fernández, S. | +22

9

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

enthalten in: International journal of hematology | 2022

von Sancho, J. | Marín-Niebla, A. | Fernández, S. | +22

10

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015) : A Multicenter, Open-Label, Single-Arm, Phase II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Giné, E. | de la Cruz, F. | Jiménez Ubieto, A. | +20

1
2
3
4
5
Nächster »
[5]